We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Mr
Christopher
Halloran
halloran@liverpool.ac.uk
Janet
Murphy
JANET.MURPHY2@liverpoolft.nhs.uk
Mr
Christopher
Halloran
halloran@liverpool.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
Benign neoplasmsMalignant neoplasms of digestive organs
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Resections of the pancreas which reach to the left of the superior mesenteric vein are defined as distal pancreatectomy and are undertaken for potential or actual malignant lesions of this portion of the pancreas. Open surgery has been considered the gold standard, however laparoscopic approaches are becoming more mainstream.
This study will evaluate potential differences in clinical and oncological effectiveness, safety, quality of life and costs between minimal-invasive and open distal pancreatectomy. The primary hypothesis is that minimal-invasive, i.e. laparoscopic distal pancreatectomy (LDP) is non-inferior to open distal pancreatectomy (ODP) in terms of postoperative mortality and
morbidity measured as the comprehensive complication index (CCI) within 3 months after intervention.
Eligible patients would be those: Undergoing planned distal pancreatectomy with or without
splenectomy for any indication; Patient suitable for both surgical techniques; Age > = 18 years; Ability of subject to understand character and individual consequences of the clinical trial and be able to undertake written informed consent.
This is a Pan-Germany study with Liverpool as the only UK site, selected because of high volume of pancreas surgery. The study will recruit over 2 year with follow-up of 2 years.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Interventional type: Surgery;
You can take part if:
You may not be able to take part if:
Patients scheduled for a pancreatic resection other than distal pancreatectomy Distant organ metastases Tumour infiltration of the superior mesenteric vein or superior mesenteric artery or hepatic artery or infiltration of adjacent organs CA 19-9 > 1000 IU/ml ASA > 3 Prior major open upper abdominal surgery Left-sided portal hypertension Participation in another interventional trial with interference of intervention and/or outcome of this study Expected lack of compliance
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Mr
Christopher
Halloran
halloran@liverpool.ac.uk
Janet
Murphy
JANET.MURPHY2@liverpoolft.nhs.uk
Mr
Christopher
Halloran
halloran@liverpool.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by University of Liverpool and funded by Deutsche Forschungsgemeinschaft .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 49731
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
